Search

Your search keyword '"Dore, Gregory J"' showing total 1,839 results

Search Constraints

Start Over You searched for: Author "Dore, Gregory J" Remove constraint Author: "Dore, Gregory J"
1,839 results on '"Dore, Gregory J"'

Search Results

203. Hepatitis C virus‐specific immune responses following direct‐acting antivirals administered during recent hepatitis C virus infection.

206. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial

211. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection

216. Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis

219. Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study.

226. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study

227. Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study

228. Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection

232. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada

243. Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies

244. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection

245. Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The REACH‐C cohort.

246. Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scale‐up of direct‐acting antiviral treatment

247. Persistent symptoms up to four months after community and hospital‐managed SARS‐CoV‐2 infection

249. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study

Catalog

Books, media, physical & digital resources